Healthcare Organ-on-a-chip Innovations Fueling Drug Screening Applications

Novel Organ-chip Platforms Likely to Transform the Drug Screening Process in the Pharmaceutical Industry

INDUSTRY
Healthcare

RELEASE DATE
29-Jun-2018
REGION
Global
DELIVERABLE TYPE
Technology Research

RESEARCH CODE
D84A-01-00-00-00
SKU
HC03038-GL-TR_22079
Yes
SHARE

Organ-on-a-chip Innovations Fueling Drug Screening Applications
Published on: 29-Jun-2018 | SKU: HC03038-GL-TR_22079

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

Organ-on-a-chip technology involves the incorporation of microphysiological systems harboring dynamic living 3D organoids, tissue-culture, or cell cultures on a microfluidic platform. The physiologically relevant Organ-chip models offer a better and more precise insight to the possible in vivo effects of drugs in the human body. The flexibility of Organ-on-a-chip is such that the innovation is not just human relevant per se but can mimic a wide variety of human functions such as breathing, heart beats, peristalsis, menstruation, neuronal communication.
Animal models and in vitro assays have served as the gold standard for pre-clinical research and study for a long time now. But for all the benefits, animal models and in vitro assays have seen poor results in human translation and prediction due to unsatisfactory human relevance. Organ-on-a-chip innovations are currently making themselves relevant by offering better data for human translation and prediction through their high degree of human relevant systems.
US are currently the frontrunners in the Organ-on-a-chip technology followed closely by Netherlands, United Kingdom and Germany. The countries have been capitalized on the need for a better study model in drug screening application to pioneer the development of Organ-on-a-chip innovations which has seen relative success in the pharmaceutical industry as evidenced by the adoption of Organ-chip technology by major pharmaceutical companies such as Roche, AstraZeneca among many others.

1.1 Research Scope – Application of Organ-on-a-chip Technology in Drug Screening Process

1.2 Research Methodology – The Frost & Sullivan Core Value

1.3 Key Findings: Organ-on-a-chip Technology

2.1 A Brief Overview of Organ-on-a-chip Functioning

2.2 Key Factors Empowering Organ-on-a-chip Technologies for Drug Screening Processes

2.3 Current Trends in the Organ-on-a-chip platform

3.1 Heart-on-a-chip Platform

3.2 Liver-on-a-chip Platform

3.2.1 High Throughput Capability of Liver-on-a-chip Platforms Integral to Large-Scale Drug Screening Applications

3.2.2 Flow Systems Adopted in Liver-on-a-chip Platforms that Facilitate Stability

3.3 Lung-on-a-chip Platform

3.3.1 Lung-on-a-chip: Platform Overview, Application, Disadvantages and Features

3.4 Kidney-on-a-chip Platform

3.4.1 Kidney-on-a-chip: Features, Platform Design, Applications, and Challenges

3.5 Gut-on-a-chip/Intestine-on-a-chip Platform

3.5.1 Intestine- and Gut-on-a-chip Serve as Enhanced Study Models

3.5.2 Intestine- and Gut-on-a-chip: The Applications and the Challenges

3.6 Nerve-on-a-chip Platform

3.6.1 Evaluation of Neurotoxicity with Nerve-on-a-chip platform

3.7 Muscle-on-a-chip Platform

3.7.1 Muscle-on-Chip Platform to Determine Long-term rug ffects on Muscle Loss and Toxicity

3.7.2 Muscle-on-a-chipPhysiology, Features and Application Areas

3.8 Brain-on-a-chip Platform

3.8.1 Emulation of Human-Blood-Brain Barrier

3.9 Multi-Organ Chip Platforms

3.10 Human-on-a-chip Platform

4.1 Drivers and Challenges Impact Chart of Organ-Chip Technology

4.2 Organ-on-a-chip Technology

4.3 Stem ell henotypes key to unlocking vast otential of Organ-chip Systems

5.1 A Well-defined and Robust Nerve-on-a-chip Platform

5.2 CN Bio- UK’s Organ-chip Technology Pioneer

5.3 Emulate propelling Drug Screening and Development through their

5.4 Hesperos facilitates superior Serum-free Media and Pumpless Organ-Chip Systems

5.5 Liver-on-a-chip platforms with High Biological Fidelity

5.6 Scaffold-free Human Relevant Liver-on-a-Chip Systems

5.7 Validated Research-ready Organ-chip Systems

5.8 Organ-Chips that facilitate High Throughput Screening

5.9 Precise Flow-controlled ParVivo Organ-Chip Systems

5.10 Replicating In Vivo Cardiac Biology on an n Vitro Chip Platform

5.11 TissUse pioneering Human-on-a-Chip platform

6.1. Patent Research Scope and Concepts

6.2 Top 20 Patent Holders in the Organ-on-a-chip Platform

6.3 Patent Office-wise Distribution of Organ-on-a-chip Patent Portfolio, 2008–2018*

6.4 Year-wise Publication Distribution of Organ-on-a-chip Patent Portfolio, 2008–2017

7.1 Funding Strength of Organ-Chip Technology- Global View

7.2 Government Funding for Organ-on-a-chip Development

7.3 Venture Capitalist-based Investment Funding in the OOC Market

7.4.Animal Free Research involved in Funding of Organ-on-a-chip Technology Development

8.1 Growth Opportunity 1: Personalized Medicine

8.2 Growth Opportunity 2: Animal Model Replacement

8.3 Growth Opportunity 3: Identification of Biomarkers

8.4 Determinants of Organ-on-a-chip Platform’s Impact on Drug Screening Process

9.1 Key Contacts

9.1 Key Contacts (continued)

Legal Disclaimer


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

15 Sep 2026   |   Global   |   Market Research

Vendor Profiles: Advanced Wound Care Management Market, Global, 2025

The wound care market is being transformed by advanced technologies and evolving care models that focus on improving patient outcomes and reducing healthcare costs. Innovations such as smart sensor-embedded dressings, artificial intelligence (AI)-based wound imaging systems, enhanced negative pressu...

11 Sep 2026   |   Global   |   Frost Radar

Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2026

Pharmaceutical commercialization is a multidimensional concept in the successful launch and distribution of a drug. The process includes the development of a pricing strategy that reflects the drug’s value, negotiation with payers to ensure drug cost coverage, regulatory compliance, and the generati...

07 Sep 2026   |   Global   |   Technology Research

Synthetic Antibodies and AI-Optimized Immunotherapies

Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion mode...

28 Aug 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Digital Solutions, and Medical Imaging Solutions

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, digital solutions, and medical imaging solutions.The issue features advanced medical devices such as active bioelectr...

27 Aug 2026   |   Global   |   Frost Radar

Frost Radar: AI-Powered Molecular Diagnostics, 2026

AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

Organ-on-a-chip technology involves the incorporation of microphysiological systems harboring dynamic living 3D organoids, tissue-culture, or cell cultures on a microfluidic platform. The physiologically relevant Organ-chip models offer a better and more precise insight to the possible in vivo effects of drugs in the human body. The flexibility of Organ-on-a-chip is such that the innovation is not just human relevant per se but can mimic a wide variety of human functions such as breathing, heart beats, peristalsis, menstruation, neuronal communication. Animal models and in vitro assays have served as the gold standard for pre-clinical research and study for a long time now. But for all the benefits, animal models and in vitro assays have seen poor results in human translation and prediction due to unsatisfactory human relevance. Organ-on-a-chip innovations are currently making themselves relevant by offering better data for human translation and prediction through their high degree of human relevant systems. US are currently the frontrunners in the Organ-on-a-chip technology followed closely by Netherlands, United Kingdom and Germany. The countries have been capitalized on the need for a better study model in drug screening application to pioneer the development of Organ-on-a-chip innovations which has seen relative success in the pharmaceutical industry as evidenced by the adoption of Organ-chip technology by major pharmaceutical companies such as Roche, AstraZeneca among many others.
More Information
Deliverable Type Technology Research
No Index No
Podcast No
Author Deepak Jayakumar
Industries Healthcare
WIP Number D84A-01-00-00-00
Is Prebook No
Ti Codes D900,D901,D90A,D90D,D90E,D910,D913,D915,D918,D91A,D91B,D930,D933,D934,D936,D937,D947-TI

Organ-on-a-chip Innovations Fueling Drug Screening Applications

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03038-GL-TR_22079